CONFERENCE ON MONOCLONAL ANTIBODIES

单克隆抗体会议

• 批准号: 3434219
• 负责人: CHARLES Frederick FOX
• 金额: $ 0.3万
• 依托单位: KEYSTONE CENTER
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-06-14 至 1992-06-13
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3434219
• 关键词: meeting /conference /symposium; monoclonal antibody; travel

Fifteen years after the first description of monoclonal antibodies, we are seeing their successful application as drugs to treat a variety of diseases. The insights and technologies of protein chemistry and molecular biology are having a significant impact on improved design of these agents. Results of recent clinical trials have identified new problems which are being rapidly addressed in the laboratory to provide new solutions. Therefore, at this juncture, there is a critical need to bring together basic and clinical scientists as well as individuals involved in process design and regulatory affairs to design strategies for the future. Along these lines, sessions at this conference will address issues in the areas of binding sites, effector mechanisms, surface receptor molecules, immunoconjugates, protein design, clinical trials, animal models, and other issues that impact on these strategies.

首次描述单克隆抗体后的十五年，我们 正在将他们成功的应用视为治疗各种药物 疾病。 蛋白质化学和 分子生物学对改进的设计有重大影响 这些代理。 最近的临床试验结果已经确定了新的 实验室正在迅速解决的问题提供 新解决方案。 因此，在这个关头，迫切需要 将基本和临床科学家以及个人汇集在一起 参与过程设计和监管事务以设计策略 未来。 沿着这些界限，会议上的会议将 解决约束地点，效应机制的问题， 表面受体分子，免疫缀合物，蛋白质设计，临床 试验，动物模型和其他影响这些策略的问题。